Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality

被引：79

作者：

Maiti, Abhishek ^{[1
,2
]}

Qiao, Wei ^{[3
]}

Sasaki, Koji ^{[1
]}

Ravandi, Farhad ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Jabbour, Elias J. ^{[1
]}

Daver, Naval G. ^{[1
]}

Borthakur, Gautam ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Pierce, Sherry A. ^{[1
]}

Montalbano, Kathryn S. ^{[1
]}

Pemmaraju, Naveen ^{[1
]}

Naqvi, Kiran ^{[1
]}

Ohanian, Maro ^{[1
]}

Short, Nicholas J. ^{[1
]}

Alvarado, Yesid ^{[1
]}

Takahashi, Koichi ^{[1
]}

Yilmaz, Musa ^{[1
]}

Jain, Nitin ^{[1
]}

Kornblau, Steven M. ^{[1
]}

Andreeff, Michael ^{[1
]}

Bose, Prithviraj ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Issa, Ghayas C. ^{[1
]}

Masarova, Lucia ^{[1
]}

Thompson, Philip A. ^{[1
]}

Rausch, Caitlin R. ^{[4
]}

Ning, Jing ^{[4
]}

Kantarjian, Hagop M. ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Konopleva, Marina Y. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1400 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 03期

基金：

美国国家卫生研究院;

关键词：

INDUCTION THERAPY; EARLY DEATH; 10-DAY DECITABINE; ELDERLY-PATIENTS; SURVIVAL; OLDER; RECOMMENDATIONS; PREDICTION; DIAGNOSIS; AML;

D O I：

10.1002/ajh.26061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are "fit" or "unfit" for IC. We compared outcomes of older patients with newly diagnosed AML receiving 10-day decitabine with venetoclax (DEC10-VEN) vs IC. DEC10-VEN consisted of daily venetoclax with decitabine 20 mg/m(2) for 10 days for induction and decitabine for 5 days as consolidation. The IC cohort received regimens containing cytarabine >= 1 g/m(2)/d. A validated treatment-related mortality score (TRMS) was used to classify patients at high-risk or low-risk for TRM with IC. Propensity scores were used to match patients to minimize bias. Median age of the DEC10-VEN cohort (n = 85) was 72 years (range 63-89) and 28% patients were at high-risk of TRM with IC. The comparator IC group (n = 85) matched closely in terms of baseline characteristics. DEC10-VEN was associated with significantly higher CR/CRi compared to IC (81% vs 52%, P < .001), and lower rate of relapse (34% vs 56%, P = .01), 30-day mortality (1% vs 24%, P < .01), and longer overall survival (OS; 12.4 vs 4.5 months, HR = 0.48, 95%CI 0.29-0.79, P < .01). In patients at both at high-risk and low-risk of TRM, DEC10-VEN showed significantly higher CR/CRi, lower 30-day mortality, and longer OS compared to IC. Patients at both high-risk and low-risk of TRM had comparable outcomes with DEC10-VEN. In conclusion, DEC10-VEN offers better outcomes compared to intensive chemotherapy in older patients with newly diagnosed AML, particularly in those at high-risk of TRM.

引用

页码：282 / 291

页数：10

共 27 条

[1]

Almeida Antonio M, 2016, Leuk Res Rep, V6, P1, DOI 10.1016/j.lrr.2016.06.001

[2] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[3] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia [J].

DiNardo, C. D. ;

Jonas, B. A. ;

Pullarkat, V. ;

Thirman, M. J. ;

Garcia, J. S. ;

Wei, A. H. ;

Konopleva, M. ;

Doehner, H. ;

Letai, A. ;

Fenaux, P. ;

Koller, E. ;

Havelange, V. ;

Leber, B. ;

Esteve, J. ;

Wang, J. ;

Pejsa, V. ;

Hajek, R. ;

Porkka, K. ;

Illes, A. ;

Lavie, D. ;

Lemoli, R. M. ;

Yamamoto, K. ;

Yoon, S. -S. ;

Jang, J. -H. ;

Yeh, S. -P. ;

Turgut, M. ;

Hong, W. -J. ;

Zhou, Y. ;

Potluri, J. ;

Pratz, K. W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :617-629

[4] 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial [J].

DiNardo, Courtney D. ;

Maiti, Abhishek ;

Rausch, Caitlin R. ;

Pemmaraju, Naveen ;

Naqvi, Kiran ;

Daver, Naval G. ;

Kadia, Tapan M. ;

Borthakur, Gautam ;

Ohanian, Maro ;

Alvarado, Yesid ;

Issa, Ghayas C. ;

Montalban-Bravo, Guillermo ;

Short, Nicholas J. ;

Yilmaz, Musa ;

Bose, Prithviraj ;

Jabbour, Elias J. ;

Takahashi, Koichi ;

Burger, Jan A. ;

Garcia-Manero, Guillermo ;

Jain, Nitin ;

Kornblau, Steven M. ;

Thompson, Philip A. ;

Estrov, Zeev ;

Masarova, Lucia ;

Sasaki, Koji ;

Verstovsek, Srdan ;

Ferrajoli, Alessandra ;

Weirda, William G. ;

Wang, Sa A. ;

Konoplev, Sergej ;

Chen, Zhining ;

Pierce, Sherry A. ;

Ning, Jing ;

Qiao, Wei ;

Ravandi, Farhad ;

Andreeff, Michael ;

Welch, John S. ;

Kantarjian, Hagop M. ;

Konopleva, Marina Y. .

LANCET HAEMATOLOGY, 2020, 7 (10) :E724-E736

[5] Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J].

DiNardo, Courtney D. ;

Pratz, Keith ;

Pullarkat, Vinod ;

Jonas, Brian A. ;

Arellano, Martha ;

Becker, Pamela S. ;

Frankfurt, Olga ;

Konopleva, Marina ;

Wei, Andrew H. ;

Kantarjian, Hagop M. ;

Xu, Tu ;

Hong, Wan-Jen ;

Chyla, Brenda ;

Potluri, Jalaja ;

Pollyea, Daniel A. ;

Letai, Anthony .

BLOOD, 2019, 133 (01) :7-17

[6] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[7] Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? [J].

Estey, Elihu ;

Karp, Judith E. ;

Emadi, Ashkan ;

Othus, Megan ;

Gale, Robert Peter .

LEUKEMIA, 2020, 34 (03) :671-681

[8] Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold? [J].

Ferrara, Felicetto .

BLOOD CANCER JOURNAL, 2020, 10 (01)

[9] The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia [J].

Giles, Francis J. ;

Borthakur, Gautam ;

Ravandi, Farhad ;

Faderl, Stefan ;

Verstovsek, Srdan ;

Thomas, Deborah ;

Wierda, William ;

Ferrajoli, Alessandra ;

Kornblau, Steven ;

Pierce, Sherry ;

Albitar, Maher ;

Cortes, Jorge ;

Kantarjian, Hagop .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) :624-627

[10] The Propensity Score [J].

Haukoos, Jason S. ;

Lewis, Roger J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (15) :1637-1638

← 1 2 3 →